Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
about
Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidaseCyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analoguesAdvanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical productsIdentification and characterization of ambroxol as an enzyme enhancement agent for Gaucher diseaseConformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.Alteration of the proteostasis network of plant cells promotes the post-endoplasmic reticulum trafficking of recombinant mutant (L444P) human β-glucocerebrosidase.Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain.A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysatesGaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidaseQUDeX-MS: hydrogen/deuterium exchange calculation for mass spectra with resolved isotopic fine structure.Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Pharmacological chaperone therapy for lysosomal storage diseases.Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseasesPharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.Emerging drugs for lysosomal storage diseases.Pharmacological chaperone therapy for Gaucher disease: a patent review.Glucocerebrosidase inhibitors for the treatment of Gaucher disease.Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase ModulatorsDiltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.2-Acetamino-1,2-dideoxynojirimycin-lysine hybrids as hexosaminidase inhibitors.Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants.Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.β-Glucocerebrosidase Modulators Promote Dimerization of β-Glucocerebrosidase and Reveal an Allosteric Binding Site.Application of H/D exchange to hydrogen bonding in small molecules.
P2860
Q24336251-9377C7E9-1E7C-4D94-A983-64065643C34FQ27667205-6BA48017-2F2E-4148-AE3A-CC732A822E48Q30402317-1F959DE4-EE75-48D9-AFE1-4199CAB9DECBQ33478327-A192CA58-0DCC-440E-A370-6768DC64717EQ33684631-0CB0F3E8-881C-4C2A-8B66-14F10FE5937AQ33870303-698A21B1-51C6-46F3-B120-5581C2633EE6Q33879008-14F1CE34-8B91-437E-B2D5-B3FFA413D2AFQ33879577-39B4CC60-0365-4606-BC48-CA095A7A622BQ33961400-29D84F04-C53F-41B1-86AB-83E619B7FFDAQ34066863-5C513358-DCD5-4DB4-931E-182004D2356AQ34286005-DCBE7699-FD42-4CCB-BEAE-43ACE4A7A252Q34761914-1D285F31-3EEB-4072-9C34-6CED0C987014Q35007910-F54894FF-009F-4807-9170-CDB1E7C45E6AQ35214286-A0D48713-700F-428C-9571-D5092817EEEFQ35904520-6CA9F8F4-9D46-42A2-B4B5-4FABCF4D404AQ36182964-5CDB27AD-0C21-4B36-B209-5B8194DFBBDAQ37354438-23A26D8E-D824-482E-8BBE-2F8AE3BFCB07Q37668227-E4875715-7A5E-4566-A4F5-8F5C15A75B41Q37765901-77C9CAB5-A5A0-4CFC-8ABA-6FE6ACC8C02CQ37860332-0C8DC7E1-DC2F-4894-AE11-B9579A5E05B7Q38097869-4106486D-BC0F-44BE-B4C1-1078775E4D14Q38824056-024ABAA7-12AC-4E34-AF4D-85A0497322D1Q39891286-724D51A6-617D-4945-A281-D8B733124629Q40993992-7B46E4A6-AB8B-4959-AEFF-C483CA2193F0Q42077651-EC5FCAAB-004B-4E44-AA21-91B7E9EA71DAQ42763507-24DF2A9F-805D-41C0-A0EA-34526E58B16CQ52574646-37158144-2262-4F95-9E50-1A04B16374BAQ54765549-C9E302E4-7085-48DE-B084-4BE5B0835D29
P2860
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Identification of pharmacologi ...... um exchange mass spectrometry.
@ast
Identification of pharmacologi ...... um exchange mass spectrometry.
@en
type
label
Identification of pharmacologi ...... um exchange mass spectrometry.
@ast
Identification of pharmacologi ...... um exchange mass spectrometry.
@en
prefLabel
Identification of pharmacologi ...... um exchange mass spectrometry.
@ast
Identification of pharmacologi ...... um exchange mass spectrometry.
@en
P2093
P2860
P356
P1433
P1476
Identification of pharmacologi ...... um exchange mass spectrometry.
@en
P2093
Brigitte A Rigat
Cecilia Murphy
Don J Mahuran
Eric D Brown
Gregory J Kornhaber
Gustavo H Maegawa
Jan E Blanchard
Justin D Buttner
Michael B Tropak
Stephen J Coales
P2860
P304
P356
10.1002/CBIC.200800304
P577
2008-11-01T00:00:00Z